
Commentary|Videos|March 27, 2025
Dr Morgans on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer
Author(s)Alicia Morgans, MD, MPH
Fact checked by: Chris Ryan
Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.
Advertisement
Alicia Morgans, MD, MPH, a physician and medical director of the Survivorship Program at Dana-Farber Cancer Institute; and an associate professor of medicine at Harvard Medical School, underscored the need to standardize the management of bone, cardiac, and other complications in patients undergoing systemic therapy for prostate cancer.
Morgans led a session on the management of the complications of systemic therapy at the 2025 Bridging the Gaps in Prostate Cancer meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































